Second psilocybin trial gets FDA 'breakthrough' status
The Food and Drug Administration has given Usona Institute's phase 2 clinical trials for psilocybin, the psychoactive chemical in magic mushrooms Breakthrough Therapy status, expediting its study.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Chemistry | Clinical Trials | Food and Drug Administration (FDA) | Health | Mushrooms | Study